Antitumour ether lipids: proapoptotic agents with multiple therapeutic indications

Bibliography

• MUNDER PG, WESTPHAL O: Antitumoral and other biomedical activities of synthetic ether lysophospholipids. Chem. Immunol. (1990) 49:206-235.
   PubMedGoogle Scholar
• HOULIHAN WJ, LOHMEYER M, WORKMAN P, CHEON SH: Phospholipid antitumor agents. Med. Res. Rev. (1995) 15:157-223.
   PubMedGoogle Scholar
• GAJATE C, MOLLINEDO F: Biological activities, mechanisms of action and biomedical prospect of the antitumor ether phospholipid ET-18-OCH3 (edelfosine), a proapoptotic agent in tumor cells. Curr. Drug. Metab. (2002) 3:491-525.
   PubMed Web of Science ®Google Scholar
• ANDREESEN R, MODOLELL M, WELTZIEN HU et al.: Selective destruction of human leukemic cells by alkyl-lysophospholipids. Cancer. Res. (1978) 38:3894-3899.
   PubMed Web of Science ®Google Scholar
• ANDREESEN R, MODOLELL M, MUNDER PG: Selective sensitivity of chronic myelogenous leukemia cell populations to alkyl-lysophospholipids. Blood (1979) 54:519-523.
   PubMedGoogle Scholar
• MODOLELL M, ANDREESEN R, PAHLKE W, BRUGGER U, MUNDER PG: Disturbance of phospholipid metabolism during the selective destruction of tumor cells induced by alkyl-lysophospholipids. Cancer Res. (1979) 39:4681-4686.
   PubMed Web of Science ®Google Scholar
• EIBL H, UNGER C: Hexadecylphosphocholine: a new and selective antitumor drug. Cancer Treat. Rev. (1990) 17:233-242.
   PubMed Web of Science ®Google Scholar
• MOLLINEDO F, GAJATE C, MARTIN-SANTAMARIA S, GAGO F: ET-18-OCH3 (edelfosine): a selective antitumour lipid targeting apoptosis through intracellular activation of Fas/CD95 death receptor. Curr. Med. Chem. (2004) 11:3163-3184.
   PubMed Web of Science ®Google Scholar
• HERRMANN DB, PAHLKE W, OPITZ HG, BICKER U: In vivo antitumor activity of ilmofosine. Cancer Treat. Rev. (1990) 17:247-252.
   PubMedGoogle Scholar
• HERRMANN DB, BICKER U, PAHLKE W: BM 41.440: a new antineoplastic, antimetastatic, and immune-stimulating drug. Cancer Detect. Prev. Suppl. (1987) 1:361-371.
   PubMedGoogle Scholar
• MARINO-ALBERNAS JR, BITTMAN R, PETERS A, MAYHEW E: Synthesis and growth inhibitory properties of glycosides of 1-O-hexadecyl-2-O-methyl-sn-glycerol, analogs of the antitumor ether lipid ET-18-OCH3 (edelfosine). J. Med. Chem. (1996) 39:3241-3247.
   PubMedGoogle Scholar
• SAMADDER P, BYUN HS, BITTMAN R, ARTHUR G: Glycosylated antitumor ether lipids are more effective against oncogene-transformed fibroblasts than alkyllysophospholipids. Anticancer Res. (1998) 18:465-470.
   PubMedGoogle Scholar
• WIESE A, WIEDER T, MICKELEIT M et al.: Structure-dependent effects of glucose-containing analogs of platelet activating factor (PAF) on membrane integrity. Biol. Chem. (2000) 381:135-144.
   PubMedGoogle Scholar
• QIAO L, NAN F, KUNKEL M, GALLEGOS A, POWIS G, KOZIKOWSKI AP: 3-Deoxy-D-myo-inositol 1-phosphate, 1-phosphonate, and ether lipid analogues as inhibitors of phosphatidylinositol-3-kinase signaling and cancer cell growth. J. Med. Chem. (1998) 41:3303-3306.
   PubMed Web of Science ®Google Scholar
• JACKSON JK, BURT HM, OKTABA AM et al.: The antineoplastic ether lipid, s-phosphonate, selectively induces apoptosis in human leukemic cells and exhibits antiangiogenic and apoptotic activity on the chorioallantoic membrane of the chick embryo. Cancer Chemother. Pharmacol. (1998) 41:326-332.
   PubMed Web of Science ®Google Scholar
• SHIN J, QUALLS MM, BOOMER JA, ROBARGE J, THOMPSON DH: An efficient new route to plasmenyl-type lipids: synthesis and cytotoxicity of a plasmenylcholine analogue of the antitumor ether lipid ET-18-OCH3. J. Am. Chem. Soc. (2001) 123:508-509.
   PubMedGoogle Scholar
• HILGARD P, KLENNER T, STEKAR J, NOSSNER G, KUTSCHER B, ENGEL J: D-21266, a new heterocyclic alkylphospholipid with antitumour activity. Eur. J. Cancer. (1997) 33:442-446.
   PubMed Web of Science ®Google Scholar
• KNEBEL NG, GRIEB S, WINKLER M, LOCHER M, VAN DER VLIS E, VERHEIJ ER: Quantification of perifosine, an alkylphosphocholine antitumour agent, in plasma by pneumatically assisted electrospray tandem mass spectrometry coupled with high-performance liquid chromatography. J. Chromatogr. B. Biomed. Sci. Appl. (1999) 721:257-269.
   PubMedGoogle Scholar
• ERDLENBRUCH B, JENDROSSEK V, MARX M, HUNOLD A, EIBL H, LAKOMEK M: Antitumor effects of erucylphosphocholine on brain tumor cells in vitro and in vivo. Anticancer Res. (1998) 18:2551-2557.
   PubMedGoogle Scholar
• JENDROSSEK V, ERDLENBRUCH B, HUNOLD A, KUGLER W, EIBL H, LAKOMEK M: Erucylphosphocholine, a novel antineoplastic ether lipid, blocks growth and induces apoptosis in brain tumor cell lines in vitro. Int. J. Oncol. (1999) 14:15-22.
   PubMedGoogle Scholar
• WIEDER T, PERLITZ C, WIEPRECHT M, HUANG RT, GEILEN CC, ORFANOS CE: Two new sphingomyelin analogues inhibit phosphatidylcholine biosynthesis by decreasing membrane-bound CTP: phosphocholine cytidylyltransferase levels in HaCaT cells. Biochem. J. (1995) 311(Pt 3):873-879.
   PubMed Web of Science ®Google Scholar
• BRACHWITZ H, BERGMANN J, FICHTNER I et al.: 1-β-D-arabinofuranosylcytosine-5'-alkyl- phosphonophosphates and diphosphates: new orally active derivatives of Ara-C. J. Lipid Res. (1998) 39:162-172.
   PubMed Web of Science ®Google Scholar
• CABANER C, GAJATE C, MACHO A, MUNOZ E, MODOLELL M, MOLLINEDO F: Induction of apoptosis in human mitogen-activated peripheral blood T lymphocytes by the ether phospholipid ET-18-OCH3: involvement of the Fas receptor/ligand system. Br. J. Pharmacol . (1999) 127:813-825.
   PubMedGoogle Scholar
• GAJATE C, SANTOS-BENEIT A, MODOLELL M, MOLLINEDO F: Involvement of c-Jun NH2-terminal kinase activation and c-Jun in the induction of apoptosis by the ether phospholipid 1-O-octadecyl-2-O-methyl-rac-glycero-3- phosphocholine. Mol. Pharmacol. (1998) 53:602-612.
   PubMedGoogle Scholar
• RUITER GA, ZERP SF, BARTELINK H, VAN BLITTERSWIJK WJ, VERHEIJ M: Alkyl-lysophospholipids activate the SAPK/JNK pathway and enhance radiation-induced apoptosis. Cancer Res. (1999) 59:2457-2463.
   PubMed Web of Science ®Google Scholar
• HIDESHIMA T, CATLEY L, YASUI H et al.: Perifosine, an oral bioactive novel alkylphospholipid, inhibits Akt and induces in vitro and in vivo cytotoxicity in human multiple myeloma cells. Blood (2006) 107:4053-4062.
   PubMed Web of Science ®Google Scholar
• RUITER GA, ZERP SF, BARTELINK H, VAN BLITTERSWIJK WJ, VERHEIJ M: Anti-cancer alkyl-lysophospholipids inhibit the phosphatidylinositol 3-kinase-Akt/PKB survival pathway. Anticancer Drugs (2003) 14:167-173.
   PubMed Web of Science ®Google Scholar
• ZHOU X, LU X, RICHARD C et al.: 1-O-octadecyl-2-O-methyl-glycerophosphocholine inhibits the transduction of growth signals via the MAPK cascade in cultured MCF-7 cells. J. Clin. Invest. (1996) 98:937-944.
   PubMed Web of Science ®Google Scholar
• SAMADDER P, RICHARDS C, BITTMAN R, BHULLAR RP, ARTHUR G: The antitumor ether lipid 1-O-octadecyl-2-O-methyl-rac-glycero- phosphocholine (ET-18-OCH3) inhibits the association between Ras and Raf-1. Anticancer Res. (2003) 23:2291-2295.
   PubMedGoogle Scholar
• SAMADDER P, ARTHUR G: Decreased sensitivity to 1-O-octadecyl-2- O-methyl-glycerophosphocholine in MCF-7 cells adapted for serum-free growth correlates with constitutive association of Raf-1 with cellular membranes. Cancer Res. (1999) 59:4808-4815.
   PubMedGoogle Scholar
• RUITER GA, VERHEIJ M, ZERP SF, MOOLENAAR WH, VAN BLITTERSWIJK WJ: Submicromolar doses of alkyl-lysophospholipids induce rapid internalization, but not activation, of epidermal growth factor receptor and concomitant MAPK/ERK activation in A431 cells. Int. J. Cancer (2002) 102:343-350.
   PubMedGoogle Scholar
• ARTHUR G, SAMADDER P, BITTMAN R: ET-18-OCH3 inhibits the phosphorylation and activation of p70 S6 kinase in MCF-7 cells. Anticancer Res. (2005) 25:95-100.
   PubMedGoogle Scholar
• BOGGS KP, ROCK CO, JACKOWSKI S: Lysophosphatidylcholine and 1-O-octadecyl-2-O-methyl-rac-glycero-3- phosphocholine inhibit the CDP-choline pathway of phosphatidylcholine synthesis at the CTP:phosphocholine cytidylyltransferase step. J. Biol. Chem. (1995) 270:7757-7764.
   PubMedGoogle Scholar
• BOGGS K, ROCK CO, JACKOWSKI S: The antiproliferative effect of hexadecylphosphocholine toward HL60 cells is prevented by exogenous lysophosphatidylcholine. Biochim. Biophys. Acta. (1998) 1389:1-12.
   PubMedGoogle Scholar
• BABURINA I, JACKOWSKI S: Apoptosis triggered by 1-O-octadecyl- 2-O-methyl-rac-glycero-3-phosphocholine is prevented by increased expression of CTP:phosphocholine cytidylyltransferase. J. Biol. Chem. (1998) 273:2169-2173.
   PubMedGoogle Scholar
• VAN DER SANDEN MH, HOUWELING M, DUIJSINGS D, VAANDRAGER AB, VAN GOLDE LM: Inhibition of phosphatidylcholine synthesis is not the primary pathway in hexadecylphosphocholine-induced apoptosis. Biochim. Biophys. Acta. (2004) 1636:99-107.
   PubMedGoogle Scholar
• ZHOU X, ARTHUR G: Effect of 1-O-octadecyl-2-O-methyl-glycerophos- phocholine on phosphatidylcholine and phosphatidylethanolamine synthesis in MCF-7 and A549 cells and its relationship to inhibition of cell proliferation. Eur. J. Biochem. (1995) 232:881-888.
   PubMedGoogle Scholar
• VAN DER LUIT AH, BUDDE M, RUURS P, VERHEIJ M, VAN BLITTERSWIJK WJ: Alkyl-lysophospholipid accumulates in lipid rafts and induces apoptosis via raft-dependent endocytosis and inhibition of phosphatidylcholine synthesis. J. Biol. Chem. (2002) 277:39541-39547.
   PubMedGoogle Scholar
• GAJATE C, DEL CANTO-JANEZ E, ACUNA AU et al.: Intracellular triggering of Fas aggregation and recruitment of apoptotic molecules into Fas-enriched rafts in selective tumor cell apoptosis. J. Exp. Med. (2004) 200:353-365.
   PubMed Web of Science ®Google Scholar
• ZAREMBERG V, GAJATE C, CACHARRO LM, MOLLINEDO F, McMASTER CR: Cytotoxicity of an anticancer lysophospholipid through selective modification of lipid raft composition. J. Biol. Chem. (2005) 280:38047-38058.
   PubMed Web of Science ®Google Scholar
• GAJATE C, MOLLINEDO F: The antitumor ether lipid ET-18-OCH3 induces apoptosis through translocation and capping of Fas/CD95 into membrane rafts in human leukemic cells. Blood (2001) 98:3860-3863.
   PubMedGoogle Scholar
• GAJATE C, MOLLINEDO F: Edelfosine and perifosine induce selective apoptosis in multiple myeloma by recruitment of death receptors and downstream signaling molecules into lipid rafts. Blood (2007) 109:711-719.
   PubMed Web of Science ®Google Scholar
• KING MT, ECKHARDT K, GOCKE E, WILD D, BERDEL WE, MUNDER PG: Failure to detect mutagenic effects of antitumor alkyl-lysophospholipids. Cancer Lett. (1981) 12:217-222.
   PubMed Web of Science ®Google Scholar
• BAUCHINGER M, DRESP J, SCHMID E, BERDEL WE: Cytogenetic effects of an alkyl-lyso- phospholipid derivative in human peripheral lymphocytes exposed in vitro and in vivo. Mutat. Res. (1983) 121:225-231.
   PubMedGoogle Scholar
• BERDEL WE, FINK U, RASTETTER J: Clinical Phase I pilot study of the alkyl lysophospholipid derivative ET-18-OCH3. Lipids (1987) 22:967-969.
   PubMedGoogle Scholar
• ANDREESEN R, OSTERHOLZ J, LUCKENBACH GA et al.: Tumor cytotoxicity of human macrophages after incubation with synthetic analogues of 2-lysophosphatidylcholine. J. Natl. Cancer Inst. (1984) 72:53-59.
   PubMed Web of Science ®Google Scholar
• VOGLER WR, OLSON AC, OKAMOTO S et al.: Comparison of selective cytotoxicity of alkyl lysophospholipids. Lipids (1991) 26:1418-1423.
   PubMedGoogle Scholar
• MOLLINEDO F, MARTINEZ-DALMAU R, MODOLELL M: Early and selective induction of apoptosis in human leukemic cells by the alkyl-lysophospholipid ET-18-OCH3. Biochem. Biophys. Res. Commun. (1993) 192:603-609.
   PubMedGoogle Scholar
• MOLLINEDO F, FERNANDEZ-LUNA JL, GAJATE C et al.: Selective induction of apoptosis in cancer cells by the ether lipid ET-18-OCH3 (edelfosine): molecular structure requirements, cellular uptake and protection by Bcl-2 and Bcl-XL. Cancer Res. (1997) 57:1320-1328.
   PubMed Web of Science ®Google Scholar
• OKAMOTO S, OLSON AC, BERDEL WE, VOGLER WR: Purging of acute myeloid leukemic cells by ether lipids and hyperthermia. Blood (1988) 72:1777-1783.
   PubMed Web of Science ®Google Scholar
• OKAMOTO S, OLSON AC, VOGLER WR: Elimination of leukemic cells by the combined use of ether lipids in vitro. Cancer Res. (1987) 47:2599-2603.
   PubMedGoogle Scholar
• DIETZFELBINGER HF, KUHN D, ZAFFERANI M, HANAUSKE AR, RASTETTER JW, BERDEL WE: Removal of breast cancer cells from bone marrow by in vitro purging with ether lipids and cryopreservation. Cancer Res. (1993) 53:3747-3751.
   PubMed Web of Science ®Google Scholar
• VOGLER WR, BERDEL WE: Autologous bone marrow transplantation with alkyl-lysophospholipid-purged marrow. J. Hematother. (1993) 2:93-102.
   PubMedGoogle Scholar
• VOGLER WR: Bone marrow purging in acute leukemia with alkyl- lysophospholipids: a new family of anticancer drugs. Leuk. Lymphoma. (1994) 13:53-60.
   PubMed Web of Science ®Google Scholar
• VOGLER WR, BERDEL WE, GELLER RB et al.: A Phase II trial of autologous bone marrow transplantation (ABMT) in acute leukemia with edelfosine purged bone marrow. Adv. Exp. Med. Biol. (1996) 416:389-396.
   PubMedGoogle Scholar
• DIOMEDE L, COLOTTA F, PIOVANI B, RE F, MODEST EJ, SALMONA M: Induction of apoptosis in human leukemic cells by the ether lipid 1-octadecyl- 2-methyl-rac-glycero-3-phosphocholine. A possible basis for its selective action. Int. J. Cancer. (1993) 53:124-130.
   PubMed Web of Science ®Google Scholar
• GAJATE C, FONTERIZ RI, CABANER C et al.: Intracellular triggering of Fas, independently of FasL, as a new mechanism of antitumor ether lipid-induced apoptosis. Int. J. Cancer (2000) 85:674-682.
   PubMedGoogle Scholar
• GAJATE C, SANTOS-BENEIT AM, MACHO A et al.: Involvement of mitochondria and caspase-3 in ET-18-OCH3-induced apoptosis of human leukemic cells. Int. J. Cancer (2000) 86:208-218.
   PubMedGoogle Scholar
• DELMAS D, REBE C, LACOUR S et al.: Resveratrol-induced apoptosis is associated with Fas redistribution in the rafts and the formation of a death-inducing signaling complex in colon cancer cells. J. Biol. Chem. (2003) 278:41482-41490.
   PubMed Web of Science ®Google Scholar
• DELMAS D, REBE C, MICHEAU O et al.: Redistribution of CD95, DR4 and DR5 in rafts accounts for the synergistic toxicity of resveratrol and death receptor ligands in colon carcinoma cells. Oncogene (2004) 23:8979-8986.
   PubMed Web of Science ®Google Scholar
• LACOUR S, HAMMANN A, GRAZIDE S et al.: Cisplatin-induced CD95 redistribution into membrane lipid rafts of HT29 human colon cancer cells. Cancer Res. (2004) 64:3593-3598.
   PubMed Web of Science ®Google Scholar
• GAJATE C, MOLLINEDO F: Cytoskeleton-mediated death receptor and ligand concentration in lipid rafts forms apoptosis-promoting clusters in cancer chemotherapy. J. Biol. Chem. (2005) 280:11641-11647.
   PubMed Web of Science ®Google Scholar
• MOLLINEDO F, GAJATE C: Fas/CD95 death receptor and lipid rafts: new targets for apoptosis-directed cancer therapy. Drug Resist. Updat. (2006) 9:51-73.
   PubMed Web of Science ®Google Scholar
• NIETO-MIGUEL T, GAJATE C, MOLLINEDO F: Differential targets and subcellular localization of antitumor alkyl-lysophospholipid in leukemic versus solid tumor cells. J. Biol. Chem. (2006) 281:14833-14840.
   PubMed Web of Science ®Google Scholar
• SCAFFIDI C, FULDA S, SRINIVASAN A et al.: Two CD95 (APO-1/Fas) signaling pathways. Embo J. (1998) 17:1675-1687.
   PubMed Web of Science ®Google Scholar
• SCAFFIDI C, SCHMITZ I, ZHA J, KORSMEYER SJ, KRAMMER PH, PETER ME: Differential modulation of apoptosis sensitivity in CD95 type I and II cells. J. Biol. Chem. (1999) 274:22532-22538.
   PubMed Web of Science ®Google Scholar
• ERAMO A, SARGIACOMO M, RICCI-VITIANI L et al.: CD95 death-inducing signaling complex formation and internalization occur in lipid rafts of type I and type II cells. Eur. J. Immunol. (2004) 34:1930-1940.
   PubMedGoogle Scholar
• MOLLINEDO F, GAJATE C, MODOLELL M: The ether lipid 1-octadecyl-2-methyl-rac-glycero-3-phos- phocholine induces expression of fos and jun proto-oncogenes and activates AP-1 transcription factor in human leukaemic cells. Biochem. J. (1994) 302:325-329.
   PubMedGoogle Scholar
• AHMAD I, FILEP JJ, FRANKLIN JC et al.: Enhanced therapeutic effects of liposome-associated 1-O-octadecyl-2-O- methyl-sn-glycero-3-phosphocholine. Cancer Res. (1997) 57:1915-1921.
   PubMedGoogle Scholar
• PETERS AC, AHMAD I, JANOFF AS, PUSHKAREVA MY, MAYHEW E: Growth inhibitory effects of liposome-associated 1-O-octadecyl-2 -O-methyl-sn-glycero-3-phosphocholine. Lipids (1997) 32:1045-1054.
   PubMedGoogle Scholar
• CUVILLIER O, MAYHEW E, JANOFF AS, SPIEGEL S: Liposomal ET-18-OCH3 induces cytochrome c-mediated apoptosis independently of CD95 (APO-1/Fas) signaling. Blood (1999) 94:3583-3592.
   PubMedGoogle Scholar
• STRASSHEIM D, SHAFER SH, PHELPS SH, WILLIAMS CL: Small cell lung carcinoma exhibits greater phospholipase C-β1 expression and edelfosine resistance compared with non-small cell lung carcinoma. Cancer Res. (2000) 60:2730-2736.
   PubMedGoogle Scholar
• SHAFER SH, WILLIAMS CL: Non-small and small cell lung carcinoma cell lines exhibit cell type-specific sensitivity to edelfosine-induced cell death and different cell line-specific responses to edelfosine treatment. Int. J. Oncol. (2003) 23:389-400.
   PubMed Web of Science ®Google Scholar
• JENDROSSEK V, HANDRICK R: Membrane targeted anticancer drugs: potent inducers of apoptosis and putative radiosensitisers. Curr. Med. Chem. Anti-Canc. Agents (2003) 3:343-353.
   PubMedGoogle Scholar
• VEHMEYER K, SCHEURICH P, EIBL H, UNGER C: Hexadecylphosphocholine- mediated enhancement of T cell responses to IL-2. Cell Immunol. (1991) 137:232-238.
   PubMedGoogle Scholar
• HOCHHUTH CH, VEHMEYER K, EIBL H, UNGER C: Hexadecylphosphocholine induces IF-γ secretion and expression of GM-CSF mRNA in human mononuclear cells. Cell Immunol. (1992) 141:161-168.
   PubMedGoogle Scholar
• BECKERS T, VOEGELI R, HILGARD P: Molecular and cellular effects of hexadecylphosphocholine (miltefosine) in human myeloid leukaemic cell lines. Eur. J. Cancer (1994) 30A:2143-2150.
   PubMedGoogle Scholar
• TERWOGT JM, MANDJES IA, SINDERMANN H, BEIJNEN JH, TEN BOKKEL HUININK WW: Phase II trial of topically applied miltefosine solution in patients with skin-metastasized breast cancer. Br. J. Cancer (1999) 79:1158-1161.
   PubMedGoogle Scholar
• LEONARD R, HARDY J, VAN TIENHOVEN G et al.: Randomized, double-blind, placebo-controlled, multicenter trial of 6% miltefosine solution, a topical chemotherapy in cutaneous metastases from breast cancer. J. Clin. Oncol. (2001) 19:4150-4159.
   PubMed Web of Science ®Google Scholar
• VERWEIJ J, GANDIA D, PLANTING AS, STOTER G, ARMAND JP: Phase II study of oral miltefosine in patients with squamous cell head and neck cancer. Eur. J. Cancer (1993) 29A:778-779.
   PubMedGoogle Scholar
• VERWEIJ J, PLANTING A, VAN DER BURG M, STOTER G: A dose-finding study of miltefosine (hexadecylphosphocholine) in patients with metastatic solid tumours. J. Cancer Res. Clin. Oncol. (1992) 118:606-608.
   PubMed Web of Science ®Google Scholar
• VERWEIJ J, KRZEMIENIECKI K, KOK T et al.: Phase II study of miltefosine (hexadecylphosphocholine) in advanced soft tissue sarcomas of the adult – an EORTC Soft Tissue and Bone Sarcoma Group Study. Eur. J. Cancer (1993) 29A:208-209.
   PubMedGoogle Scholar
• PLANTING AS, STOTER G, VERWEIJ J: Phase II study of daily oral miltefosine (hexadecylphosphocholine) in advanced colorectal cancer. Eur. J. Cancer (1993) 29A:518-519.
   PubMedGoogle Scholar
• KONDAPAKA SB, SINGH SS, DASMAHAPATRA GP, SAUSVILLE EA, ROY KK: Perifosine, a novel alkylphospholipid, inhibits protein kinase B activation. Mol. Cancer Ther. (2003) 2:1093-1103.
   PubMed Web of Science ®Google Scholar
• MOMOTA H, NERIO E, HOLLAND EC: Perifosine inhibits multiple signaling pathways in glial progenitors and cooperates with temozolomide to arrest cell proliferation in gliomas in vivo. Cancer Res. (2005) 65:7429-7435.
   PubMed Web of Science ®Google Scholar
• PATEL V, LAHUSEN T, SY T, SAUSVILLE EA, GUTKIND JS, SENDEROWICZ AM: Perifosine, a novel alkylphospholipid, induces p21(WAF1) expression in squamous carcinoma cells through a p53-independent pathway, leading to loss in cyclin-dependent kinase activity and cell cycle arrest. Cancer Res. (2002) 62:1401-1409.
   PubMed Web of Science ®Google Scholar
• NYAKERN M, CAPPELLINI A, MANTOVANI I, MARTELLI AM: Synergistic induction of apoptosis in human leukemia T cells by the Akt inhibitor perifosine and etoposide through activation of intrinsic and Fas-mediated extrinsic cell death pathways. Mol. Cancer Ther. (2006) 5:1559-1570.
   PubMed Web of Science ®Google Scholar
• VAN UMMERSEN L, BINGER K, VOLKMAN J et al.: A Phase I trial of perifosine (NSC 639966) on a loading dose/maintenance dose schedule in patients with advanced cancer. Clin. Cancer Res. (2004) 10:7450-7456.
   PubMed Web of Science ®Google Scholar
• VINK SR, SCHELLENS JH, VAN BLITTERSWIJK WJ, VERHEIJ M: Tumor and normal tissue pharmacokinetics of perifosine, an oral anti-cancer alkylphospholipid. Invest. New Drugs (2005) 23:279-286.
   PubMed Web of Science ®Google Scholar
• CRUL M, ROSING H, DE KLERK GJ et al.: Phase I and pharmacological study of daily oral administration of perifosine (D-21266) in patients with advanced solid tumours. Eur. J. Cancer (2002) 38:1615-1621.
   PubMed Web of Science ®Google Scholar
• BAILEY HH, MAHONEY MR, ETTINGER DS et al.: Phase II study of daily oral perifosine in patients with advanced soft tissue sarcoma. Cancer (2006) 107:2462-2467.
   PubMed Web of Science ®Google Scholar
• KNOWLING M, BLACKSTEIN M, TOZER R et al.: A Phase II study of perifosine (D-21226) in patients with previously untreated metastatic or locally advanced soft tissue sarcoma: A National Cancer Institute of Canada Clinical Trials Group trial. Invest. New Drugs (2006) 24:435-439.
   PubMed Web of Science ®Google Scholar
• POSADAS EM, GULLEY J, ARLEN PM et al.: A Phase II study of perifosine in androgen independent prostate cancer. Cancer Biol. Ther. (2005) 4:1133-1137.
   PubMed Web of Science ®Google Scholar
• ERNST DS, EISENHAUER E, WAINMAN N et al.: Phase II study of perifosine in previously untreated patients with metastatic melanoma. Invest. New Drugs (2005) 23:569-575.
   PubMed Web of Science ®Google Scholar
• ARGIRIS A, COHEN E, KARRISON T et al.: A Phase II trial of perifosine, an oral alkylphospholipid, in recurrent or metastatic head and neck cancer. Cancer Biol. Ther. (2006) 5:766-770.
   PubMed Web of Science ®Google Scholar
• MARSH RD, LIMA CM, LEVY DE, MITCHELL EP, ROWLAND KM, Jr., BENSON AB III: A Phase II trial of perifosine in locally advanced, unresectable, or metastatic pancreatic adenocarcinoma. Am. J. Clin. Oncol. (2007) 30:26-31.
   PubMed Web of Science ®Google Scholar
• RAHMANI M, REESE E, DAI Y et al.: Coadministration of histone deacetylase inhibitors and perifosine synergistically induces apoptosis in human leukemia cells through Akt and ERK1/2 inactivation and the generation of ceramide and reactive oxygen species. Cancer Res. (2005) 65:2422-2432.
   PubMed Web of Science ®Google Scholar
• VINK SR, LAGERWERF S, MESMAN E et al.: Radiosensitization of squamous cell carcinoma by the alkylphospholipid perifosine in cell culture and xenografts. Clin. Cancer Res. (2006) 12:1615-1622.
   PubMed Web of Science ®Google Scholar
• VINK SR, SCHELLENS JH, BEIJNEN JH et al.: Phase I and pharmacokinetic study of combined treatment with perifosine and radiation in patients with advanced solid tumours. Radiother. Oncol. (2006) 80:207-213.
   PubMed Web of Science ®Google Scholar
• DE LA PENA L, BURGAN WE, CARTER et al.: Inhibition of Akt by the alkylphospholipid perifosine does not enhance the radiosensitivity of human glioma cells. Mol. Cancer Ther. (2006) 5:1504-1510.
   PubMedGoogle Scholar
• JENDROSSEK V, KUGLER W, ERDLENBRUCH B, EIBL H, LANG F, LAKOMEK M: Erucylphosphocholine- induced apoptosis in chemoresistant glioblastoma cell lines: involvement of caspase activation and mitochondrial alterations. Anticancer Res. (2001) 21:3389-3396.
   PubMed Web of Science ®Google Scholar
• JENDROSEK V, HAMMERSEN K, ERDLENBRUCH B et al.: Structure–activity relationships of alkylphosphocholine derivatives: antineoplastic action on brain tumor cell lines in vitro. Cancer Chemother. Pharmacol. (2002) 50:71-79.
   PubMedGoogle Scholar
• ERDLENBRUCH B, JENDROSSEK V, GERRIETS A, VETTERLEIN F, EIBL H, LAKOMEK M: Erucylphosphocholine: pharmacokinetics, biodistribution and CNS-accumulation in the rat after intravenous administration. Cancer Chemother. Pharmacol. (1999) 44:484-490.
   PubMed Web of Science ®Google Scholar
• ERDLENBRUCH B, JENDROSSEK V, KUGLER W, EIBL H, LAKOMEK M: Increased delivery of erucylphosphocholine to C6 gliomas by chemical opening of the blood–brain barrier using intracarotid pentylglycerol in rats. Cancer Chemother. Pharmacol. (2002) 50:299-304.
   PubMed Web of Science ®Google Scholar
• RUBEL A, HANDRICK R, LINDNER LH et al.: The membrane targeted apoptosis modulators erucylphosphocholine and erucylphosphohomocholine increase the radiation response of human glioblastoma cell lines in vitro. Radiat. Oncol. (2006) 1:6.
   PubMedGoogle Scholar
• HANDRICK R, RUBEL A, FALTIN H, EIBL H, BELKA C, JENDROSSEK V: Increased cytotoxicity of ionizing radiation in combination with membrane-targeted apoptosis modulators involves downregulation of protein kinase B/Akt-mediated survival-signaling. Radiother. Oncol. (2006) 80:199-206.
   PubMed Web of Science ®Google Scholar
• JENDROSSEK V, MULLER I, EIBL H, BELKA C: Intracellular mediators of erucylphosphocholine-induced apoptosis. Oncogene (2003) 22:2621-2631.
   PubMed Web of Science ®Google Scholar
• KUGLER W, BUCHHOLZ F, KOHLER F, EIBL H, LAKOMEK M, ERDLENBRUCH B: Downregulation of Apaf-1 and caspase-3 by RNA interference in human glioma cells: consequences for erucylphosphocholine-induced apoptosis. Apoptosis (2005) 10:1163-1174.
   PubMedGoogle Scholar
• KUGLER W, ERDLENBRUCH B, OTTEN K, JENDROSSEK V, EIBL H, LAKOMEK M: MAP kinase pathways involved in glioblastoma response to erucylphosphocholine. Int. J. Oncol. (2004) 25:1721-1727.
   PubMed Web of Science ®Google Scholar
• KONSTANTINOV SM, BERGER MR: Human urinary bladder carcinoma cell lines respond to treatment with alkylphosphocholines. Cancer Lett. (1999) 144:153-160.
   PubMed Web of Science ®Google Scholar
• KONSTANTINOV SM, EIBL H, BERGER MR: BCR-ABL influences the antileukaemic efficacy of alkylphosphocholines. Br. J. Haematol. (1999) 107:365-380.
   PubMed Web of Science ®Google Scholar
• CROFT SL, SEIFERT K, DUCHENE M: Antiprotozoal activities of phospholipid analogues. Mol. Biochem. Parasitol. (2003) 126:165-172.
   PubMed Web of Science ®Google Scholar
• TSUSHIMA S, YOSHIOKA Y, TANIDA S, NOMURA H, NOJIMA S, HOZUMI M: Syntheses and antimicrobial activities of alkyl lysophospholipids. Chem. Pharm. Bull. (Tokyo) (1982) 30:3260-3270.
   PubMed Web of Science ®Google Scholar
• ACHTERBERG V, GERCKEN G: Cytotoxicity of ester and ether lysophospholipids on Leishmania donovani promastigotes. Mol. Biochem. Parasitol. (1987) 23:117-122.
   PubMed Web of Science ®Google Scholar
• CROFT SL, NEAL RA, PENDERGAST W, CHAN JH: The activity of alkyl phosphorylcholines and related derivatives against Leishmania donovani. Biochem. Pharmacol. (1987) 36:2633-2636.
   PubMed Web of Science ®Google Scholar
• BERDEL WE, BAUSERT WR, FINK U, RASTETTER J, MUNDER PG: Antitumor action of alkyl- lysophospholipids (review). Anticancer Res. (1981) 1:345-352.
   PubMed Web of Science ®Google Scholar
• BERDEL WE: Membrane-interactive lipids as experimental anticancer drugs. Br. J. Cancer (1991) 64:208-211.
   PubMedGoogle Scholar
• CROFT SL, NEAL RA, THORNTON EA, HERRMANN DB: Antileishmanial activity of the ether phospholipid ilmofosine. Trans. R. Soc. Trop. Med. Hyg. (1993) 87:217-219.
   PubMed Web of Science ®Google Scholar
• ESCOBAR P, MATU S, MARQUES C, CROFT SL: Sensitivities of Leishmania species to hexadecylphosphocholine (miltefosine), ET-18-OCH3 (edelfosine) and amphotericin B. Acta. Trop. (2002) 81:151-157.
   PubMed Web of Science ®Google Scholar
• YARDLEY V, CROFT SL, DE DONCKER S et al.: The sensitivity of clinical isolates of Leishmania from Peru and Nepal to miltefosine. Am. J. Trop. Med. Hyg. (2005) 73:272-275.
   PubMed Web of Science ®Google Scholar
• SANTA-RITA RM, HENRIQUES-PONS A, BARBOSA HS, DE CASTRO SL: Effect of the lysophospholipid analogues edelfosine, ilmofosine and miltefosine against Leishmania amazonensis. J. Antimicrob. Chemother. (2004) 54:704-710.
   PubMed Web of Science ®Google Scholar
• CROFT SL, SNOWDON D, YARDLEY V: The activities of four anticancer alkyllysophospholipids against Leishmania donovani, Trypanosoma cruzi and Trypanosoma brucei. J. Antimicrob. Chemother. (1996) 38:1041-1047.
   PubMed Web of Science ®Google Scholar
• SEIFERT K, DUCHENE M, WERNSDORFER WH et al.: Effects of miltefosine and other alkylphosphocholines on human intestinal parasite Entamoeba histolytica. Antimicrob. Agents Chemother. (2001) 45:1505-1510.
   PubMed Web of Science ®Google Scholar
• WALOCHNIK J, DUCHENE M, SEIFERT K et al.: Cytotoxic activities of alkylphosphocholines against clinical isolates of Acanthamoeba spp. Antimicrob. Agents Chemother. (2002) 46:695-701.
   PubMed Web of Science ®Google Scholar
• PARIS C, LOISEAU PM, BORIES C, BREARD J: Miltefosine induces apoptosis-like death in Leishmania donovani promastigotes. Antimicrob. Agents Chemother. (2004) 48:852-859.
   PubMed Web of Science ®Google Scholar
• VERMA NK, DEY CS: Possible mechanism of miltefosine-mediated death of Leishmania donovani. Antimicrob. Agents Chemother. (2004) 48:3010-3015.
   PubMed Web of Science ®Google Scholar
• LINDOSO JA, COTRIM PC, GOTO H: Apoptosis of Leishmania chagasi amastigotes in hamsters infected with visceral leishmaniasis. Int. J. Parasitol. (2004) 34:1-4.
   PubMedGoogle Scholar
• KUHLENCORD A, MANIERA T, EIBL H, UNGER C: Hexadecylphosphocholine: oral treatment of visceral leishmaniasis in mice. Antimicrob. Agents Chemother. (1992) 36:1630-1634.
   PubMed Web of Science ®Google Scholar
• SUNDAR S, JHA TK, THAKUR CP, BHATTACHARYA SK, RAI M: Oral miltefosine for the treatment of Indian visceral leishmaniasis. Trans. R. Soc. Trop. Med. Hyg. (2006) 100(Suppl. 1):S26-S33.
   PubMedGoogle Scholar
• MURRAY HW, DELPH-ETIENNE S: Visceral leishmanicidal activity of hexadecylphosphocholine (miltefosine) in mice deficient in T cells and activated macrophage microbicidal mechanisms. J. Infect. Dis. (2000) 181:795-799.
   PubMed Web of Science ®Google Scholar
• MURRAY HW: Suppression of posttreatment recurrence of experimental visceral Leishmaniasis in T cell-deficient mice by oral miltefosine. Antimicrob. Agents Chemother. (2000) 44:3235-3236.
   PubMed Web of Science ®Google Scholar
• ESCOBAR P, YARDLEY V, CROFT SL: Activities of hexadecylphosphocholine (miltefosine), ambisome, and sodium stibogluconate (pentostam) against Leishmania donovani in immunodeficient scid mice. Antimicrob. Agents Chemother. (2001) 45:1872-1875.
   PubMed Web of Science ®Google Scholar
• LAWN SD, WILKINSON RJ: Immune reconstitution disease associated with parasitic infections following antiretroviral treatment. Parasite Immunol. (2006) 28:625-633.
   PubMed Web of Science ®Google Scholar
• JHA TK, SUNDAR S, THAKUR CP et al.: Miltefosine, an oral agent, for the treatment of Indian visceral leishmaniasis. N. Engl. J. Med. (1999) 341:1795-1800.
   PubMed Web of Science ®Google Scholar
• SUNDAR S, JHA TK, THAKUR CP et al.: Oral miltefosine for Indian visceral leishmaniasis. N. Engl. J. Med. (2002) 347:1739-1746.
   PubMed Web of Science ®Google Scholar
• SOTO J, ARANA BA, TOLEDO J et al.: Miltefosine for new world cutaneous leishmaniasis. Clin. Infect. Dis. (2004) 38:1266-1272.
   PubMed Web of Science ®Google Scholar
• SOTO J, BERMAN J: Treatment of New World cutaneous leishmaniasis with miltefosine. Trans. R. Soc. Trop. Med. Hyg. (2006) 100(Suppl. 1):S34-S40.
   Google Scholar
• DESJEUX P: Leishmaniasis. Public health aspects and control. Clin. Dermatol. (1996) 14:417-423.
   PubMed Web of Science ®Google Scholar
• SCHWARTZ E, HATZ C, BLUM J: New world cutaneous leishmaniasis in travellers. Lancet Infect. Dis. (2006) 6:342-349.
   PubMed Web of Science ®Google Scholar
• BAKER D, O'NEILL JK, AMOR S, KHAMASHTA MA, TURK JL: Inhibition of chronic relapsing experimental allergic encephalomyelitis in the mouse by the alkyl-lysophospholipid ET-18-OCH3. Int. J. Immunopharmacol. (1991) 13:385-392.
   PubMedGoogle Scholar
• KLEIN-FRANKE A, MUNDER PG: Alkyllysophospholipid prevents induction of experimental allergic encephalomyelitis. J. Autoimmun. (1992) 5:83-91.
   PubMedGoogle Scholar
• CHABANNES D, RYFFEL B, BOREL JF: SRI 62-834, a cyclic ether analogue of the phospholipid ET-18-OCH3, displays long-lasting beneficial effect in chronic relapsing experimental allergic encephalomyelitis in the Lewis rat. Comparison with cyclosporin and (Val2)-dihydrocyclosporin effects in clinical, functional and histological studies. J. Autoimmun. (1992) 5:199-211.
   PubMedGoogle Scholar
• KOVARIK J, CHABANNES D, BOREL JF: Immunoregulation and drug treatment in chronic relapsing experimental allergic encephalomyelitis in the Lewis rat. Int. J. Immunopharmacol. (1995) 17:255-263.
   PubMedGoogle Scholar
• ZAMVIL S, NELSON P, TROTTER J et al.: T cell clones specific for myelin basic protein induce chronic relapsing paralysis and demyelination. Nature (1985) 317:355-358.
   PubMed Web of Science ®Google Scholar
• ACHA-ORBEA H, MITCHELL DJ, TIMMERMANN L et al.: Limited heterogeneity of T cell receptors from lymphocytes mediating autoimmune encephalomyelitis allows specific immune intervention. Cell (1988) 54:263-273.
   PubMed Web of Science ®Google Scholar
• ENGELHARDT B, DIAMANTSTEIN T, WEKERLE H: Immunotherapy of experimental autoimmune encephalomyelitis (EAE): differential effect of anti-IL-2 receptor antibody therapy on actively induced and T-line mediated EAE of the Lewis rat. J. Autoimmun. (1989) 2:61-73.
   PubMed Web of Science ®Google Scholar
• ANDREESEN R, MODOLELL M, WELTZIEN HU, MUNDER PG: Alkyl-lysophospholipid induced suppression of human lymphocyte response to mitogens and selective killing of lymphoblasts. Immunobiology (1980) 156:498-508.
   PubMedGoogle Scholar
• KUCERA LS, IYER N, LEAKE E et al.: Novel membrane-interactive ether lipid analogs that inhibit infectious HIV-1 production and induce defective virus formation. AIDS Res Hum. Retroviruses (1990) 6:491-501.
   PubMed Web of Science ®Google Scholar
• PIANTADOSI C, MARASCO CJ, Jr., MORRIS-NATSCHKE SL et al.: Synthesis and evaluation of novel ether lipid nucleoside conjugates for anti-HIV-1 activity. J. Med. Chem. (1991) 34:1408-1414.
   PubMed Web of Science ®Google Scholar
• DETMAR M, GEILEN CC, WIEDER T, ORFANOS CE, REUTTER W: Phospholipid analogue hexadecylphosphocholine inhibits proliferation and phosphatidylcholine biosynthesis of human epidermal keratinocytes in vitro. J. Invest. Dermatol. (1994) 102:490-494.
   PubMedGoogle Scholar
• 48th ASH Annual Meeting, Orlando, Florida. December 9 – 12 (2006) Abstract 3582.
   Google Scholar